Abstract
The effect of baclofen on spasticity and muscle spasms was assessed in thirty-five patients with multiple sclerosis. Benefit from reduction of spasticity was obtained in sixteen patients. A higher proportion of patients confined to a wheelchair was helped than ambulant patients, but overall functional improvement was limited. Twenty-one of the thirty-five patients had troublesome spasms and thirteen of them had significant relief on baclofen. Substituting identical dummy tablets confirmed that benefit was attributable to the pharmacological effects of baclofen in ten of the sixteen patients whose spasticity was reduced and in eight of the thirteen whose muscle spasms were relieved. In two of the remainder, benefit appeared to be due to placebo effect, and the others maintained their improvement after stopping the drug.
The drug had to be withdrawn in nine patients because of increased weakness and in ten other patients who had intolerable side effects. The optimum dose of baclofen tolerated ranged from 15 mg to 80 mg daily. The importance of adjusting the dose regime to the requirement of each individual and starting with small doses in multiple sclerosis is emphasized.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ASHWORTH B. PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. Practitioner. 1964 Apr;192:540–542. [PubMed] [Google Scholar]
- Ashby P., White D. G. "Presynaptic" inhibition in spasticity and the effect of beta(4-chlorophenyl)GABA. J Neurol Sci. 1973 Nov;20(3):329–338. doi: 10.1016/0022-510x(73)90194-9. [DOI] [PubMed] [Google Scholar]
- Burke D., Andrews C. J., Knowles L. The action of a GABA derivative in human spasticity. J Neurol Sci. 1971 Oct;14(2):199–208. doi: 10.1016/0022-510x(71)90089-x. [DOI] [PubMed] [Google Scholar]
- Burke D., Ashby P. Are spinal "presynaptic" inhibitory mechanisms suppressed in spasticity? J Neurol Sci. 1972 Mar;15(3):321–326. doi: 10.1016/0022-510x(72)90073-1. [DOI] [PubMed] [Google Scholar]
- Curtis D. R., Felix D. GABA and prolonged spinal inhibition. Nat New Biol. 1971 Jun 9;231(23):187–188. doi: 10.1038/newbio231187a0. [DOI] [PubMed] [Google Scholar]
- Hudgson P., Weightman D. Baclofen in the treatment of spasticity. Br Med J. 1971 Oct 2;4(5778):15–17. doi: 10.1136/bmj.4.5778.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jerusalem F. Doppeltblindstudie über den antispastischen Effekt von beta-(4-Chlorphenyl)-gamma-aminobuttersäure (CIBA) bei Multipler Sklerose. Nervenarzt. 1968 Nov;39(11):515–517. [PubMed] [Google Scholar]
- Jones R. F., Burke D., Marosszeky J. E., Gillies J. D. A new agent for the control of spasticity. J Neurol Neurosurg Psychiatry. 1970 Aug;33(4):464–468. doi: 10.1136/jnnp.33.4.464. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knutsson E., Lindblom U., Mårtensson A. Differences in effects in gamma and alpha spasticity induced by the GABA derivative baclofen (Lioresal). Brain. 1973;96(1):29–46. doi: 10.1093/brain/96.1.29. [DOI] [PubMed] [Google Scholar]
- Mclellan D. L., Maclellan D. L. Effect of baclofen upon monosynaptic and tonic vibration reflexes in patients with spasticity. J Neurol Neurosurg Psychiatry. 1973 Aug;36(4):555–560. doi: 10.1136/jnnp.36.4.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pedersen E., Arlien-Soborg P., Grynderup V., Henriksen O. Gaba derivative in spasticity. (Beta-(4-chlorophenyl)-gamma-aminobutyric acid, Ciba 34.647-Ba). Acta Neurol Scand. 1970;46(3):257–266. doi: 10.1111/j.1600-0404.1970.tb05791.x. [DOI] [PubMed] [Google Scholar]
- Tudor M. A. Letter: Treatment of spasticity. Lancet. 1974 Jan 26;1(7848):136–136. doi: 10.1016/s0140-6736(74)92369-1. [DOI] [PubMed] [Google Scholar]